Atorvastatin - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:19Z

Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T17:25:49Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T16:43:50Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

← Older revision		Revision as of 16:43, 20 March 2026
Line 50:		Line 50:
	==Comments==		==Comments==



			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Atorvastatin]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|link=subject
			\|sort=Has Indication
			\|limit=50
			}}

	==See Also==		==See Also==

2023-09-13T20:26:10Z

Adverse Reactions

2023-09-13T20:25:38Z

Special Populations

← Older revision		Revision as of 20:25, 13 September 2023
Line 17:		Line 17:

	==Special Populations==		==Special Populations==
			*[[Pregnancy Rating]]: X
	*Pregnancy Rating: X
	*Lactation risk: Generally not recommended while breastfeeding		*Lactation risk: Generally not recommended while breastfeeding
	*Renal Dosing		*Renal Dosing

2023-09-13T19:36:57Z

Adult Dosing

← Older revision		Revision as of 19:36, 13 September 2023
Line 9:		Line 9:
	*Moderate Intensity: 10-20 mg PO daily		*Moderate Intensity: 10-20 mg PO daily
	*High Intensity: 40-80 mg PO daily		*High Intensity: 40-80 mg PO daily
	===Acute ~~Coronary Syndrome~~===
			===[[Acute coronary syndrome]]===
	*80 mg PO (Single dose prior to PCI)		*80 mg PO (Single dose prior to PCI)

2023-08-20T16:00:38Z

Mechanism of Action

← Older revision		Revision as of 16:00, 20 August 2023
Line 45:		Line 45:

	==Mechanism of Action==		==Mechanism of Action==
			*Inhibits rate-limiting step in cholesterol biosynthesis by inhibiting HMG-COA reductase.
			*Additionally known to have "pleiotropic effects", which include plaque stabilization, improved endothelial function, decreased oxidative stress and inflammation, and thrombogenic response inhibition.<ref>Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. doi: 10.1146/annurev.pharmtox.45.120403.095748. PMID: 15822172; PMCID: PMC2694580.</ref>

	==Comments==		==Comments==

2023-08-20T15:54:52Z

Pharmacology

← Older revision		Revision as of 15:54, 20 August 2023
Line 40:		Line 40:

	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: Approximately 14 hours<ref>McIver LA, Siddique MS. Atorvastatin. [Updated 2022 Nov 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430779/</ref>
	*Metabolism:		*Metabolism: Metabolized by cytochrome CYP3A4
	*Excretion:		*Excretion: Metabolites are eliminated via bile.

	==Mechanism of Action==		==Mechanism of Action==

2023-08-20T15:50:55Z

Special Populations

← Older revision		Revision as of 15:50, 20 August 2023
Line 16:		Line 16:

	==Special Populations==		==Special Populations==
	~~===[[Drug pregnancy categories\|Pregnancy Rating]]===~~
	*

	~~===~~Lactation risk~~===~~		*Pregnancy Rating: X
	*		*Lactation risk: Generally not recommended while breastfeeding
			*Renal Dosing
	~~===~~Renal Dosing~~===~~		**No adjustment
	*~~Adult:~~		*Hepatic Dosing
	*~~Pediatric:~~		**Contraindicated in patients with active liver disease

	~~===~~Hepatic Dosing~~===~~
	*~~Adult:~~
	*~~Pediatric:~~

	==Contraindications==		==Contraindications==

2023-08-20T15:44:05Z

Adverse Reactions